Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1Phase 1 1

Status

Completed 20Terminated 4Recruiting 4Active not recruiting 4Unknown 3Not yet recruiting 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Non-Small-Cell Lung 47Breast Neoplasms 39Ovarian Neoplasms 35Triple Negative Breast Neoplasms 24Endometrial Neoplasms 20Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 17Fallopian Tube Neoplasms 17Lung Neoplasms 16Esophageal Squamous Cell Carcinoma 14Parkinson Disease 4, Autosomal Dominant Lewy Body 13Neoplasm Metastasis 13Esophageal Neoplasms 13Neoplasms 12Uterine Cervical Neoplasms 11Carcinoma, Ovarian Epithelial 10Head and Neck Neoplasms 7Recurrence 6Carcinoma 6Colorectal Neoplasms 5Adenocarcinoma 5Uterine Neoplasms 4Small Cell Lung Carcinoma 4Oropharyngeal Neoplasms 4Melanoma 4Carcinoma, Transitional Cell 4Advanced Solid Tumors 4Adenocarcinoma Of Esophagus 4Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3

Interventions

Nivolumab 11Oxaliplatin 6Fluorouracil 6Capecitabine 5pembrolizumab 4Paclitaxel 4Leucovorin 4durvalumab 3Radiotherapy 3Folfox protocol 3Drug Therapy 3dehydroftorafur 2Trastuzumab 2Specimen Handling 2Radiation 2Metformin 2Magnetic Resonance Spectroscopy 2Itraconazole 2Irinotecan 2Docetaxel 2Cisplatin 2Carboplatin 2zolbetuximab 1zanidatamab 1trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab deruxtecan 1toripalimab 1tislelizumab 1pertuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Adenocarcinoma Of Esophagus × Paclitaxel × Clear all
NCT06203600 2026-05-26

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
224 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT05954312 2026-05-08

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

Vividion Therapeutics, Inc.

Phase 1 Recruiting
290 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Neoplasms

NCT06846346 2026-04-28

GRACIE

UNICANCER

Phase 2 Recruiting
88 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Neoplasm Metastasis, Neoplasms

NCT05188313 2022-06-24

TRAP-2

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 3 Recruiting
376 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡